TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix

Journal of Translational Medicine

Franco M Buonaguro³  Stefano Greggi¹  Simona Losito²  Luigi Buonaguro³  Clorinda Annunziata³  Maria Lina Tornesello³ 

[1] Uro-gynecology Department, Istituto Nazionale Tumori ¿Fond Pascale¿ - IRCCS ¿ Via Mariano Semmola, Napoli, 80131, Italy;Pathology Department, Istituto Nazionale Tumori ¿Fond Pascale¿ - IRCCS ¿ Via Mariano Semmola, Napoli, 80131, Italy;Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori ¿Fond Pascale¿ - IRCCS ¿ Via Mariano Semmola, Napoli, 80131, Italy

关键词: Cervical intraepithelial neoplasia;    Adenocarcinoma;    Squamous cell carcinoma;    Cervix;    PIK3CA gene;    TP53 gene;   

Others  :  1148081
DOI  :  10.1186/s12967-014-0255-5

 received in 2014-06-27, accepted in 2014-09-04,  发布年份 2014

【 摘 要 】

Background

Mutations in the tumor suppressor gene TP53 and proto-oncogene PIK3CA and alterations of p53 and PIK3CA AKT mTOR pathways are common events in several human cancers. We focused on the analysis of TP53 and PIK3CA gene variations in adenocarcinoma, squamous cell carcinoma as well as in intraepithelial neoplasia grade 3 of the cervix.

Methods

DNA samples from 28 cervical adenocarcinoma, 55 squamous cell carcinoma and 31 intraepithelial neoplasia grade 3 (CIN3), previously characterized in terms of human papillomavirus (HPV) prevalence and genotype distribution, were analyzed for TP53 and PIK3CA mutations in the exons 4¿9 and exon 9, respectively.

Results

Single nucleotide substitutions in TP53 and PIK3CA genes were detected in 36% and 11% of adenocarcinoma, in 16% and in 5% of squamous cell carcinoma, and in 13% and none of CIN 3, respectively. Nucleotide changes in TP53 were significantly more frequent in adenocarcinoma cases than in squamous cell carcinoma and CIN3 (P?=?0.035) and were independent from HPV infection status.

Conclusions

Mutations in the TP53 gene and to lesser extent in the PIK3CA gene seem more frequent in cervical adenocarcinoma than in squamous cell carcinoma and CIN3. Whether TP53 and PIK3CA gene mutations have an impact on prognosis and response to molecularly targeted therapies as well as in cytotoxic drugs in different cervical cancer histotypes needs to be analyzed in investigative clinical trials.

【 授权许可】

   
2014 Tornesello et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France; 2013.
• [2]Spriggs AI, Boddington MM: Progression and regression of cervical lesions. Review of smears from women followed without initial biopsy or treatment. J Clin Pathol 1980, 33:517-522.
• [3]Christopherson WM, Nealon N, Gray LA Sr: Noninvasive precursor lesions of adenocarcinoma and mixed adenosquamous carcinoma of the cervix uteri. Cancer 1979, 44:975-983.
• [4]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El GF, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V: A review of human carcinogens¿Part B: biological agents. Lancet Oncol 2009, 10:321-322.
• [5]Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ: Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014, 14:395-405.
• [6]Moody CA, Laimins LA: Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010, 10:550-560.
• [7]Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2:342-350.
• [8]Hafner N, Driesch C, Gajda M, Jansen L, Kirchmayr R, Runnebaum IB, Dürst M: Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008, 27:1610-1617.
• [9]Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, Hershman DL, Wright JD: Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 2012, 125:287-291.
• [10]Tornesello ML, Buonaguro L, Buonaguro FM: Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol 2013, 128:442-448.
• [11]Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A, Zehbe I: The role of TP53 in Cervical carcinogenesis. Hum Mutat 2003, 21:307-312.
• [12]Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD: Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 2006, 118:1877-1883.
• [13]Zhang A, Maner S, Betz R, Angstrom T, Stendahl U, Bergman F, Zetterberg A, Wallin KL: Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer 2002, 101:427-433.
• [14]Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, et al.: Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. Cancer Res 2002, 62:4860-4866.
• [15]Alonio LV, Picconi MA, Dalbert D, Mural J, Bartt O, Bazan G, Dominguez M, Teyssié AR: Ha-ras oncogene mutation associated to progression of papillomavirus induced lesions of uterine cervix. J Clin Virol 2003, 27:263-269.
• [16]Cheung TH, Lo KW, Yim SF, Chan LK, Heung MS, Chan CS, Cheung AY, Chung TK, Wong YF: Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol Oncol 2004, 93:621-627.
• [17]Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T, Shimamura T, Miller DS, Sharpless NE, Bardeesy N, Kwiatkowski DJ, Schorge JO, Wong KK, Castrillon DH: Somatic LKB1 mutations promote cervical cancer progression. PLoS One 2009, 4:e5137.
• [18]Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Treviño V, Vazquez-Santillan K, Guadarrama AS, Wright AA, Rosenberg MW, Duke F, Kaplan B, Wang R, Nickerson E, Walline HM, Lawrence MS, Stewart C, Carter SL, McKenna A, Rodriguez-Sanchez IP, Espinosa-Castilla M, Woie K, Bjorge L, Wik E: Landscape of genomic alterations in cervical carcinomas. Nature 2014, 506:371-375.
• [19]Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Signer SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weslon A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342:705-708.
• [20]Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M: TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26:2157-2165.
• [21]Munro AJ, Lain S, Lane DP: P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005, 92:434-444.
• [22]Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307-310.
• [23]Vousden KH: Switching from life to death: the Miz-ing link between Myc and p53. Cancer Cell 2002, 2:351-352.
• [24]Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on mutation patterns and tumor phenotype: lessons from recent developments in the IARC database. Hum Mutat 2007, 28:622-629.
• [25]Karakas B, Bachman KE, Park BH: Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006, 94:455-459.
• [26]McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, Lees-Miller SP, Ghatage P, Magliocco AM, Doll CM: PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol 2013, 128:409-414.
• [27]Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY: PIK3CA as an oncogene in cervical cancer. Oncogene 2000, 19:2739-2744.
• [28]Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van HP, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS: Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 2013, 119:3776-3783.
• [29]Carnero A: Novel inhibitors of the PI3K family. Expert Opin Investig Drugs 2009, 18:1265-1277.
• [30]Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012, 30:777-782.
• [31]Tornesello ML, Losito S, Benincasa G, Fulciniti F, Botti G, Greggi S, Buonaguro L, Buonaguro FM: Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 2011, 121:32-42.
• [32]Carozzi FM, Tornesello ML, Burroni E, Loquercio G, Carillo G, Angeloni C, Scalisi A, Macis R, Chini F, Buonaguro FM, Giorgi Rossi P: Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy. Cancer Epidemiol Biomarkers Prev 2010, 19:2389-2400.
• [33]Young RH, Clement PB: Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology 2002, 41:185-207.
• [34]Fredricks DN, Relman DA: Paraffin removal from tissue sections for digestion and PCR analysis. Biotechniques 1999, 26:198-200.
• [35]Doorbar J: The papillomavirus life cycle. J Clin Virol 2005, 32(Suppl 1):S7-S15.
• [36]Annunziata C, Buonaguro L, Buonaguro FM, Tornesello ML: Characterization of the human papillomavirus (HPV) integration sites into genital cancers. Pathol Oncol Res 2012, 18:803-808.
• [37]Schmutte C, Yang AS, Nguyen TT, Beart RW, Jones PA: Mechanisms for the involvement of DNA methylation in colon carcinogenesis. Cancer Res 1996, 56:2375-2381.
• [38]Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Harrington AM, Shields PG, Felley-Bosco E, Hussain SP, Harris CC: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999, 91:86-88.
• [39]Vaninetti NM, Geldenhuys L, Porter GA, Risch H, Hainaut P, Guernsey DL, Casson AG: Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Mol Carcinog 2008, 47:275-285.
• [40]Jackson AL, Loeb LA: The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001, 477:7-21.
• [41]Matsumoto M, Furihata M, Kurabayashi A, Araki K, Sasaguri S, Ohtsuki Y: Association between inducible nitric oxide synthase expression and p53 status in human esophageal squamous cell carcinoma. Oncology 2003, 64:90-96.
• [42]Harima Y, Sawada S, Nagata K, Sougawa M, Ohnishi T: Chromosome 6p21.2, 18q21.2 and human papilloma virus (HPV) DNA can predict prognosis of cervical cancer after radiotherapy. Int J Cancer 2001, 96:286-296.
• [43]Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR: The Catalogue of Somatic Mutations in Cancer (COSMIC).Curr Protoc Hum Genet 2008, 57:?. 10.11.1-10.11.26 doi: 10.1002/0471142905.hg1011s57.
• [44]Cui B, Zheng B, Zhang X, Stendahl U, Andersson S, Wallin KL: Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. Int J Oncol 2009, 34:409-416.
• [45]Spaans VM, Trietsch MD, Crobach S, Stelloo E, Kremer D, Osse EM, Haar NT, van Eijk R, Muller S, van Wezel T, Trimbos JB, Bosse T, Smit VT, Fleuren GJ: Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers. PLoS One 2014, 9:e93451.
• [46]Thomas LK, Bermejo JL, Vinokurova S, Jensen K, Bierkens M, Steenbergen R, Bergmann M, von Knebel Doeberitz M, Reuschenbach M: Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract - a systematic review and meta-analysis. Eur J Cancer 2014, 50:85-98.
• [47]Heselmeyer K, Schröck E, du Manoir S, Blegen H, Shah K, Steinbeck R, Auer G, Ried T: Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A 1996, 93:479-484.
• [48]Heselmeyer-Haddad K, Sommerfeld K, White NM, Chaudhri N, Morrison LE, Palanisamy N, Wang ZY, Auer G, Steinberg W, Ried T: Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol 2005, 166:1229-1238.
• [49]Yang YC, Shyong WY, Chang MS, Chen YJ, Lin CH, Huang ZD, Wang TY, Hsu MT, Chen ML: Frequent gain of copy number on the long arm of chromosome 3 in human cervical adenocarcinoma. Cancer Genet Cytogenet 2001, 131:48-53.
• [50]Luhn P, Houldsworth J, Cahill L, Schiffman M, Castle PE, Zuna RE, Dunn ST, Gold MA, Walker J, Wentzensen N: Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results. Gynecol Oncol 2013, 130:595-600.
• [51]Seppo A, Jalali GR, Babkowski R, Symiakaki H, Rodolakis A, Tafas T, Tsipouras P, Kilpatrick MW: Gain of 3q26: a genetic marker in low-grade squamous intraepithelial lesions (LSIL) of the uterine cervix. Gynecol Oncol 2009, 114:80-83.